ASCO24: Nimbus plots path for next-gen IO therapies with strong early HPK1 blocker data
Nimbus Therapeutics’ small molecule drug candidate NDI-101150 showed strong potential for clinical benefit in patients with advanced solid tumors, the Boston-based biotech announced.